NICE Says Patient Benefits Of Breast Cancer Drug Are Too Small To Justify Its Very Hi
 

The National Institute for Health and Clinical Excellence (NICE) has been asked to assess whether bevacizumab (Avastin, Roche Products), when used in combination with a taxane (a type of chemotherapy), would be a useful and cost-effective treatment option for people with breast cancer which has spread to other parts of the body...

More...